Medtronic said the three-year results from the Endeavor IV trial comparing its zotarolimus‐eluting stent and BoSci’s paclitaxel‐eluting stent in 1,548 patients show a nearly 50 percent reduction in the risk of heart attack or cardiac death with the Endeavor stent.
Boston Scientific Corp. enrolled more than 1,500 patients in the Platinum clinical trial of its Promus Element drug-eluting stent, two months ahead of schedule, setting the stage for approval applications to the Food & Drug Administration and the Japanese Ministry of Health, Labor and Welfare.
The Natick, Mass.-based medical devices giant said the workhorse trial is a global, randomized, pivotal controlled study of its platinum chromium Promus Element everolimus-eluting stent involving 1,532 patients at more than 140 sites worldwide.
Boston Scientific Corp. spent the past two days touting a trio of studies of its defibrillator and stent products, which delivered generally positive results for the Natick, Mass.-based devices giant.
But the results didn’t translate into a stock price boost; after briefly flirting with its yearlong high, BSX stock fell back to earth and was trading at $11.00 as of about 12:15 p.m. Sept. 2.
Judge Susan Robinson of the U.S. District Court for Delaware denied Wyeth’s motion to disqualify Howrey LLP as the Natick, Mass.-based device maker’s counsel, despite Howrey’s representation of Wyeth in a separate, unrelated case in Europe.
Dr. Bruce Saffran, fresh from a $500 million court victory and a private settlement with Boston Scientific over a drug-eluting stent patent, is suing Abbott Laboratories (PDF) for violating the same patent with its Xience V stent.
Saffran, a New Jersey radiologist, won the half-billion-dollar verdict against the Natick, Mass.-based devices giant and later settled for an undisclosed amount (although BoSci later posted a $50 million charge on the deal).
The device, which competes with Boston Scientific‘s Taxus product, uses a different drug, everolimus, than the paclitaxel-eluting Taxus. The drugs are designed to inhibit the re-growth of vascular tissue around the mesh-like stent.
A pair of studies published in Cardiology Today delivered positive results for Boston Scientific Corp.‘s Taxus and Taxus Express drug-eluting stents.
The first study compared the Taxus paclitaxel-eluting stent with Johnson & Johnson subsidiary Cordis Corp.’s Cypher sirolimus-eluting stent in a total of 6,035 patients. It indicated that, a year after implantation with either device, patients showed “similar rates of clinically important restenosis and ischemic complications.”